Compare Cassava Sciences Inc (FLNA) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Trip.com Group Ltd — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Trip.com Group Ltd trades at $43.86 (market cap $26.95B). The key difference: Trip.com Group Ltd is far larger — about 507.2× Cassava Sciences Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TCOM | |
|---|---|---|
Market Cap | $53.14M | $26.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $78.96 |
52-Week Low | $1.09 | $39.84 |
Enterprise Value | -$33.43M | $19.65B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Trip.com Group (TCOM) trades at $43.72, up 3.09% with strong profitability (net margin 48.65%) and attractive valuations (P/E 6.44). Recent Q1 2026 earnings missed estimates at $0.83 vs. $0.85 expected, though revenue grew 17% year-over-year. Technical indicators show mixed signals with bullish oscillators but overbought RSI levels, while support sits near $42.
Outlook remains positive with 67% analyst buy ratings and a $56.72 consensus target, but near-term risks include regulatory scrutiny in China and Q2 revenue guidance of 3%-8% growth lagging expectations. The stock offers value but faces execution and sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
